Is Sigma Labs Inc. (NASDAQ: SGLB) Back In The Buying Zone?


Susquehanna Investment Group LLC recently announced the acquisition of new stake in Sigma Labs Inc. (NASDAQ:SGLB). This fresh investment now brings its stake to 0.33% valued currently at $34970.0. In addition, UBS Securities LLC raised its holdings by 1366.0 to 1775.0 shares.

With over 67.06 million Sigma Labs Inc. (SGLB) shares trading Tuesday and a closing price of $2.87 on the day, the dollar volume was approximately $192.46 million. The shares have shown a positive weekly performance of 10.81% and its price on 08/25/20 gained nearly 15.26%. Currently, there are 3.26M common shares owned by the public and among those 2.86M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for SGLB have a consensus price objective of $5.00. The analysts have set the share’s price value over the next 12 months at a high of $5.00 and a low of $5.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Sigma Labs Inc. stock is 2.00 for the next 12 months. But an upside of 42.6% will see the stock hit the forecast high price target while mean target price for the stock is $5.00.

Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Sigma Labs Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Perritt Ultra Micro Cap Fund. Vanguard Extended Market Index Fu owns 7054.0 shares of the company’s stock, all valued at over $18975.0. Perritt Ultra Micro Cap Fund sold 11000.0 shares to bring its total holdings to over 0.0 shares at a value of $0.0. Perritt Ultra Micro Cap Fund now owns shares totaling to 0.00% of the shares outstanding.

Shares of Sigma Labs Inc. (NASDAQ: SGLB) opened at $4.05, up $1.56 from a prior closing price of $2.49. However, the script later closed the day at $2.87, up 15.26%. The company’s stock has a 5-day price change of 10.81% and 12.11% over the past three months. SGLB shares are trading -70.77% year to date (YTD), with the 12-month market performance down to -60.14% lower. It has a 12-month low price of $1.97 and touched a high of $11.70 over the same period. Currently, 67.06 million shares have been traded, compared to an average intraday trading volume of 359.07K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.00%, 8.49%, and -45.32% respectively.

Institutional ownership of Sigma Labs Inc. (NASDAQ: SGLB) shares accounts for 0.40% of the company’s 3.26M shares outstanding. Mutual fund holders own 0.24%, while other institutional holders and individual stakeholders account for 1.17% and 0.17% respectively.

It has a market capitalization of $11.31M and a beta (3y monthly) value of 0.89. The earnings-per-share (ttm) stands at -$4.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 22.74% over the week and 10.38% over the month.

Analysts forecast that Sigma Labs Inc. (SGLB) will achieve an EPS of $Schlumberger N.V. for the current quarter, $19.26 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Selecta Biosciences, Inc. while analysts give the company a high EPS estimate of $Highland Global Allocation Fund. Comparatively, EPS for the current quarter was $Shares Long-Term Corporate Bond a year ago.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Sigma Labs Inc. (SGLB) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”


Please enter your comment!
Please enter your name here